Clinical Trial Pathway Development

Guidance on study design, protocol development, Saudi Clinical Trials Registry preparation, ethics coordination, and regional regulatory approvals.

Built for Teams Preparing Clinical Evidence

We support MedTech companies that need a clear, compliant route from study concept to regional clinical trial approval.

MedTech innovators

Strategic mapping to guide complex emerging products, including bio-printed matrices and advanced biologic-device combination systems.

SaMD Developers

Prepare clinical validation pathways for software, AI, and connected health technologies.

International Manufacturers

Adapt global protocols to Saudi requirements, local ethics review, and regional evidence needs.

Clinical Operations Teams

Coordinate documentation, registry steps, and approval workflows before study activation.

Clinical Pathways Built for Approval

We translate clinical, regulatory, and ethics requirements into a practical pathway for Saudi and regional study approval.

Study Pathway Mapping

We define the required clinical route based on device classification, intended use, risk profile, and target market needs.

Protocol Development Support

We help structure protocol content, endpoints, eligibility criteria, and evidence plans for regulatory review.

Regulatory Submission Planning

We prepare the documentation strategy for SFDA and regional authority interactions before trial initiation.

Registry & Ethics Coordination

We support Saudi Clinical Trials Registry preparation, IRB coordination, and ethics committee submission workflows.

Clinical Evidence Alignment

We align study outputs with technical file, market authorization, and post-market evidence requirements.

How We Work

A focused pathway for moving from clinical concept to compliant study approval.

Define

Clarify intended use, study purpose, and regulatory evidence needs.

Design

Shape protocol structure, endpoints, and clinical documentation requirements.

Prepare

Assemble submission materials, registry inputs, and ethics documentation.

Coordinate

Support authority, IRB, and stakeholder interactions through review.

Advance

Connect approved study outputs to authorization and lifecycle evidence plans.

Key Deliverables

Clear outputs that drive compliance, reduce risk, and accelerate your time to market.

01

02

03

04

05 Build a Complete Regulatory Ecosystem .

LexoraMed provides integrated regulatory support across Saudi Arabia, GCC, and global markets — helping manufacturers move from strategy to authorization with confidence and clarity.

Medical Device Market Authorization

Advisory on securing MDMA, SFDA approvals, and global authorization pathways for regional and international market entry.

Technical File Assessment

Leading comprehensive reviews of innovative device dossiers, successfully translating advanced clinical data, cybersecurity parameters, and biocompatibility profiles into robust regulatory submissions.

Post-Market Surveillance

Ongoing compliance, vigilance, safety monitoring, reporting, and lifecycle support after market authorization.

Frequently Asked Questions

Clear answers to the most common regulatory and compliance questions manufacturers ask before entering Saudi Arabia and global markets.

When should clinical pathway planning begin? +

It should begin before protocol finalization so study design, endpoints, and evidence outputs align with regulatory expectations from the start.

Can global clinical protocols be used in Saudi Arabia? +

Often yes, but they may need adaptation for local regulatory expectations, ethics review, registry requirements, and population considerations.

Do you support SCTR preparation? +

Yes. We help prepare the information and documentation needed for Saudi Clinical Trials Registry readiness.

Is this only for high-risk devices? +

No. The pathway depends on classification, intended use, and evidence gaps; lower-risk devices may still need clinical rationale or supporting evidence.